Does the media refer more to CAI or MTD?

In the previous week, Mettler-Toledo International had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Mettler-Toledo International and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Mettler-Toledo International's score of 1.01 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, MEDP or CAI?

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.79 $451.12M $17.06 36.06 Caris Life Sciences $812.03M 10.76 -$68.09M $0.36 85.89

Does the media prefer MEDP or CAI?

In the previous week, Medpace had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Medpace and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Medpace's score of 0.86 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RVTY or CAI?

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 5.74 $241.20M $2.10 69.92 Caris Life Sciences $812.03M 10.76 -$68.09M $0.36 85.89

Does the media prefer RVTY or CAI?

In the previous week, Revvity had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Revvity and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Revvity's score of 0.78 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CAI or ICLR?

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caris Life Sciences $812.03M 10.76 -$68.09M $0.36 85.89 Icon $8.25B 1.57 $229.34M $4.26 39.83

Does the media favor CAI or ICLR?

In the previous week, Caris Life Sciences had 9 more articles in the media than Icon. MarketBeat recorded 10 mentions for Caris Life Sciences and 1 mentions for Icon. Icon's average media sentiment score of 1.32 beat Caris Life Sciences' score of 1.11 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Icon 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Caris Life Sciences (CAI) Competitors

$30.92 +2.71 (+9.61%)

Closing price 04:00 PM Eastern

Extended Trading

$31.06 +0.14 (+0.45%)

As of 07:42 PM Eastern

Compare

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

Should you buy Caris Life Sciences stock or one of its competitors? Caris Life Sciences's main competitors and comparable companies include Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), Charles River Laboratories International (CRL), and Icon (ICLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Caris Life Sciences compare to Mettler-Toledo International?

Caris Life Sciences (NASDAQ:CAI) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Mettler-Toledo International has higher revenue and earnings than Caris Life Sciences. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	10.76	-$68.09M	$0.36	85.89
Mettler-Toledo International	$4.03B	7.02	$869.19M	$44.43	31.76

Caris Life Sciences currently has a consensus target price of $26.50, suggesting a potential downside of 14.29%. Mettler-Toledo International has a consensus target price of $1,446.36, suggesting a potential upside of 2.49%. Given Mettler-Toledo International's higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, Mettler-Toledo International had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Mettler-Toledo International and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Mettler-Toledo International's score of 1.01 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Caris Life Sciences' net margin of 10.62%. Caris Life Sciences' return on equity of 18.77% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

95.1% of Mettler-Toledo International shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mettler-Toledo International beats Caris Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Medpace?

Medpace (NASDAQ:MEDP) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Medpace currently has a consensus target price of $595.20, indicating a potential downside of 3.25%. Caris Life Sciences has a consensus target price of $26.50, indicating a potential downside of 14.29%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Medpace had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Medpace and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Medpace's score of 0.86 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.79	$451.12M	$17.06	36.06
Caris Life Sciences	$812.03M	10.76	-$68.09M	$0.36	85.89

Medpace has a net margin of 17.67% compared to Caris Life Sciences' net margin of 10.62%. Medpace's return on equity of 110.15% beat Caris Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Caris Life Sciences	10.62%	18.77%	9.34%

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Medpace beats Caris Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Revvity?

Revvity (NYSE:RVTY) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

86.7% of Revvity shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Revvity presently has a consensus price target of $116.57, suggesting a potential downside of 20.61%. Caris Life Sciences has a consensus price target of $26.50, suggesting a potential downside of 14.29%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Revvity has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

In the previous week, Revvity had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 11 mentions for Revvity and 10 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.11 beat Revvity's score of 0.78 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	5.74	$241.20M	$2.10	69.92
Caris Life Sciences	$812.03M	10.76	-$68.09M	$0.36	85.89

Caris Life Sciences has a net margin of 10.62% compared to Revvity's net margin of 8.16%. Caris Life Sciences' return on equity of 18.77% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Caris Life Sciences	10.62%	18.77%	9.34%

Summary

Caris Life Sciences beats Revvity on 11 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Charles River Laboratories International?

Caris Life Sciences (NASDAQ:CAI) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

98.9% of Charles River Laboratories International shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Caris Life Sciences has a net margin of 10.62% compared to Charles River Laboratories International's net margin of -5.96%. Caris Life Sciences' return on equity of 18.77% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Caris Life Sciences currently has a consensus target price of $26.50, suggesting a potential downside of 14.29%. Charles River Laboratories International has a consensus target price of $273.81, suggesting a potential downside of 2.78%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Caris Life Sciences has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	10.76	-$68.09M	$0.36	85.89
Charles River Laboratories International	$4.02B	3.35	-$144.34M	-$4.85	N/A

Caris Life Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, Caris Life Sciences had 4 more articles in the media than Charles River Laboratories International. MarketBeat recorded 10 mentions for Caris Life Sciences and 6 mentions for Charles River Laboratories International. Caris Life Sciences' average media sentiment score of 1.11 beat Charles River Laboratories International's score of 0.95 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caris Life Sciences beats Charles River Laboratories International on 10 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Icon?

Caris Life Sciences (NASDAQ:CAI) and Icon (NASDAQ:ICLR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Caris Life Sciences currently has a consensus price target of $26.50, indicating a potential downside of 14.29%. Icon has a consensus price target of $170.40, indicating a potential upside of 0.42%. Given Icon's higher probable upside, analysts plainly believe Icon is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

95.6% of Icon shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Caris Life Sciences has a net margin of 10.62% compared to Icon's net margin of 3.99%. Caris Life Sciences' return on equity of 18.77% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Icon	3.99%	8.02%	4.56%

Caris Life Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Icon has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	10.76	-$68.09M	$0.36	85.89
Icon	$8.25B	1.57	$229.34M	$4.26	39.83

In the previous week, Caris Life Sciences had 9 more articles in the media than Icon. MarketBeat recorded 10 mentions for Caris Life Sciences and 1 mentions for Icon. Icon's average media sentiment score of 1.32 beat Caris Life Sciences' score of 1.11 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caris Life Sciences and Icon tied by winning 8 of the 16 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.97B	$10.28B	$7.20B	$14.12B
Dividend Yield	N/A	1.46%	2.57%	12.64%
P/E Ratio	85.89	69.97	273.27	25.54
Price / Sales	10.76	107.92	649.14	92.14
Price / Cash	17.69	26.83	77.01	51.20
Price / Book	15.08	5.71	10.51	6.31
Net Income	-$68.09M	$56.67B	$3.48B	$357.99M
7 Day Performance	28.62%	3.57%	0.33%	0.29%
1 Month Performance	42.95%	3.21%	-0.21%	-3.13%
1 Year Performance	N/A	29.40%	22.63%	6.88%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	3.2714 of 5 stars	$30.92 +9.6%	$26.50 -14.3%	N/A	$7.97B	$812.03M	85.89	1,846	Positive News Analyst Upgrade Insider Trade
MTD Mettler-Toledo International	3.9572 of 5 stars	$1,293.95 +1.0%	$1,446.36 +11.8%	+8.2%	$25.92B	$4.03B	29.12	18,100
MEDP Medpace	2.4187 of 5 stars	$587.52 +0.7%	$595.20 +1.3%	+25.6%	$16.40B	$2.53B	34.44	6,200	Positive News Analyst Forecast Insider Trade
RVTY Revvity	2.6068 of 5 stars	$124.46 +2.9%	$116.57 -6.3%	+71.2%	$13.87B	$2.86B	59.27	11,000
CRL Charles River Laboratories International	2.1914 of 5 stars	$278.02 +1.8%	$265.69 -4.4%	+80.5%	$13.28B	$4.02B	N/A	19,700	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Caris Life Sciences compare to Mettler-Toledo International?

Summary

How does Caris Life Sciences compare to Medpace?

Summary

How does Caris Life Sciences compare to Revvity?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Summary

How does Caris Life Sciences compare to Icon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Caris Life Sciences compare to Mettler-Toledo International?

Which has better earnings & valuation, CAI or MTD?

Do analysts prefer CAI or MTD?

Does the media refer more to CAI or MTD?

Which has more risk & volatility, CAI or MTD?

Is CAI or MTD more profitable?

Do institutionals & insiders hold more shares of CAI or MTD?

Summary

How does Caris Life Sciences compare to Medpace?

Do analysts prefer MEDP or CAI?

Which has more risk and volatility, MEDP or CAI?

Does the media prefer MEDP or CAI?

Which has preferable earnings & valuation, MEDP or CAI?

Is MEDP or CAI more profitable?

Do institutionals and insiders believe in MEDP or CAI?

Summary

How does Caris Life Sciences compare to Revvity?

Do insiders & institutionals hold more shares of RVTY or CAI?

Do analysts prefer RVTY or CAI?

Which has more risk & volatility, RVTY or CAI?

Does the media prefer RVTY or CAI?

Which has stronger earnings & valuation, RVTY or CAI?

Is RVTY or CAI more profitable?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Do institutionals and insiders hold more shares of CAI or CRL?

Is CAI or CRL more profitable?

Do analysts recommend CAI or CRL?

Which has stronger valuation & earnings, CAI or CRL?

Which has more risk and volatility, CAI or CRL?

Does the media refer more to CAI or CRL?

Summary

How does Caris Life Sciences compare to Icon?

Do analysts rate CAI or ICLR?

Do insiders & institutionals believe in CAI or ICLR?

Is CAI or ICLR more profitable?

Which has more risk & volatility, CAI or ICLR?

Which has stronger valuation & earnings, CAI or ICLR?

Does the media favor CAI or ICLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools